Embodiment
Below in conjunction with accompanying drawing, by the embodiment of the present invention, further illustrate essentiality content of the present invention, but with this, do not limit the present invention.Should be appreciated that, these embodiment are only for the present invention is described but not limit the scope of the invention.The specific experiment method that embodiment adopts and experiment condition are this area ordinary method and condition, or manufacturer method and the condition of recommending.Unless otherwise defined, identical with known to scientific words and those skilled in the art of specialty used in literary composition.
In the following examples, following compound and intermediate characterize by liquid chromatography-mass spectrography (LC-MS) and nucleus magnetic resonance (NMR), and the initial substance and the reagent that in the described compound of preparation, use can be buied or prepare by method known to those skilled in the art from supplier.General synthetic route only for example understands and can synthesize the method for the compounds of this invention by it below, and for reference to those skilled in the art of the disclosure of invention, the multiple modification of described synthetic route be can work it out and take a hint.
Unless otherwise indicated, in the present invention, disclosed experimental technique, detection method, preparation method all adopt the routine techniques of organic chemistry, analytical chemistry, cell cultures, recombinant DNA technology and the association area of the art routine.These technology are existing perfect explanation in existing document, specifically can be referring to MOLECULAR CLONING such as Sambrook: A LABORATORY MANUAL, Second edition, Cold Spring Harbor Laboratory Press, 1989 and Third edition, 2001; Ausubel etc., CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, John Wiley & Sons, New York, 1987 and periodic updates; The series METHODS IN ENZYMOLOGY, Academic Press, San Diego; Wolffe, CHROMATIN STRUCTURE AND FUNCTION, Third edition, Academic Press, San Diego, 1998; METHODS IN ENZYMOLOGY, Vol.304, Chromatin (P.M.Wassarman and A.P.Wolffe, eds.), Academic Press, San Diego, 1999; With METHODS IN MOLECULAR BIOLOGY, Vol.119, Chromatin Protocols (P.B.Becker, ed.) Humana Press, Totowa, 1999 etc.
Embodiment 1
The preparation of the compounds of this invention:
Synthetic route is as shown in Figure 1:
(1) take Lycorine prepares intermediate 1:5-methyl-4-vinyl-5,6-dihydro-[1,3 as raw material] dioxolo[4,5-j] phenanthridine:
Narcissine (Lycorine) (28.7mg, 0.1mmol) dissolves solution to N, N-dimethyl formamide (DMF) (5mL) in, add methyl iodide (MeI) (17.0mg, 0.12mmol), stirring reaction 12h at 50 ℃, underpressure distillation is directly used in next step reaction after going out solvent, under nitrogen protection condition, compound (the 30.2mg that upper step is made, 0.1mmol) solvent in the trimethyl carbinol (t-BuOH) (5mL) in, back flow reaction 4h after adding potassium tert.-butoxide (t-BuOK) (30mg), after finishing, reaction adds ammonium chloride solution, then add extracted with diethyl ether 2 times (2 * 10ml), then with 2 times (2 * 10ml) of ammonium chloride solution washing, with saturated common salt water washing 2 times (2 * 10ml), organic layer is with using anhydrous magnesium sulfate drying after saturated common salt washing, decompression is used silica gel chromatography column purification (ethyl acetate/petroleum ether 200:1 after removing volatile solvent, R
f=0.23), obtain intermediate 1,21.2mg, yield 80%.
NMR, MS analysis confirmation product:
1H?NMR?(400?MHz,?CDCl
3)?δ:?7.58?(d,?J?=?7.7?Hz,?1H),?7.47?(d,?J?=?7.7?Hz,?1H),?7.26?(dt,?J?=?10.7,?7.1?Hz,?2H),?7.16?(t,?J?=?7.7?Hz,?1H),?6.72?(s,?1H),?5.99?(s,?2H),?5.75?(d,?J?=?17.8?Hz,?1H),?5.32?(d,?J?=?11.1?Hz,?1H),?4.03?(s,?2H),?2.51?(s,?3H);?
13C?NMR?(100?MHz,?CDCl
3)?δ:?147.4?(C),?145.1?(C),?133.4?(CH),?133.2?(C),?129.2?(C),?126.4?(C),?125.8?(C),?124.9?(CH),?124.3?(CH),?122.7?(CH),?114.3?(CH
2),?107.1?(CH),?103.6?(CH),?100.9?(CH
2),?54.8?(CH
2),?41.5?(CH),?EIMS?m/z:?266?[M+H]
+.
(2) prepare compound 2:N-methyl-4-ethyl-5 from 1 further of intermediate, 6-dihydro-8,9-bis-Oxymethylenes-phenanthridines (4-ethyl-5-methyl-5,6-dihydro-[1,3] dioxolo[4,5-j] phenanthridine)
Under nitrogen protection condition; intermediate 1(26.5mg; 0.1mmol) be dissolved in methylene dichloride (5mL); then add to 10% Pd/C (30mg); in nitrogen atmosphere, react 30h; reaction finishes rear filtration, and filtrate decompression is used silica gel chromatography column purification (ethyl acetate/petroleum ether 200:1, R after removing volatile solvent
f=0.21), obtain compound 2.Yellow solid 26.8mg, yield 95%.Product m.p.(fusing point) 179-180 ° C.
NMR, MS analysis confirmation product:
1H?NMR?(400?MHz,?MeOD)?δ:?7.51?(t,?J?=?8.4?Hz,?1H),?7.28?(d,?J?=?6.4?Hz,?2H),?7.20?(t,?J?=?7.9?Hz,?2H),?6.75?(s,?1H),?6.01?(s,?1H),?4.01?(s,?2H),?2.83?(q,?J?=?7.5?Hz,?2H),?2.50?(s,?3H),?1.32?(dd,?J?=?15.7,?8.2?Hz,?3H);
13C?NMR?(100?MHz,?CDCl
3)?δ:?147.3?(C),?147.1?(C),?145.4?(C),?139.4?(C),?129.3?(C),?127.7?(CH),?126.6?(C),?126.3?(C),?124.6?(CH),?121.0?(CH),?107.2?(CH),?103.7?(CH),?100.9?(CH
2),?55.2?(CH
2),?41.02?(CH),?23.1?(CH
2),?14.8?(CH
3),?HREIMS?m/z?217.1261?[M]
+?(calcd?for?C
17H
17NO
2,?267.1259).
(3) from compound 1, prepare intermediate 3:4-ethenyl-5-methyl-5,6-dihydrophenanthridine-8,9-diol, under-78 ℃ of conditions, is dissolved into methylene dichloride (CH at compound 1 (26mg, 0.1mmol)
2cl
2) (2mL) in, add boron tribromide (BBr
3) (49.4mg, 0.2mmol) reaction 2h, after finishing, reaction adds sodium hydrogen carbonate solution, then add extracted with diethyl ether 2 times (2 * 10ml), then with 2 times (2 * 10ml) of sodium hydrogen carbonate solution washing, with saturated common salt water washing 2 times (2 * 10ml), organic layer is rear with anhydrous magnesium sulfate drying with saturated common salt washing, decompression is used silica gel chromatography column purification (ethyl acetate/petroleum ether 1:1, R after removing volatile solvent
f=0.22), obtain intermediate 3, yellow solid 16.8mg, yield 74%.
NMR, MS analysis confirmation product:
1H?NMR?(400?MHz,?DMSO)?δ?7.59-7.49?(m,?2H),?7.41?(d,?J?=?7.6?Hz,?1H),?7.19?–?7.08?(m,?2H),?6.65?(s,?1H),?5.76?(d,?J?=?17.9?Hz,?1H),?5.27?(d,?J?=?11.4?Hz,?1H),?4.23?(s,?2H),?3.87?(s,?3H);
?13C?NMR?(150?MHz,?DMSO)?δ?153.39?(C),?149.58?(C),?138.22?(CH),?133.15?(CH),?132.75?(C),?132.05?(C),?131.04?(C),?128.92?(CH),?125.57?(C),?123.98?(CH),?118.65?(C),?118.39?(CH
2),?113.46?(CH),?107.33?(CH),?62.34?(CH
2),?50.72?(CH
3);?HREIMS?m/z?253.1109?[M]
+?(calcd?for?C
16H
15NO
2,?253.1103).
(4) from compound 2s, prepare intermediate 4:4-ethyl-5-methyl-5,6-dihydrophenanthridine-8,9-diol, under-78 ℃ of conditions, is dissolved into methylene dichloride (CH at compound 2 (26.7mg, 0.1mmol)
2cl
2) (2mL) in, add boron tribromide (BBr
3) (49.4mg, 0.2mmol) reaction 2h, after finishing, reaction adds sodium hydrogen carbonate solution, then add extracted with diethyl ether 2 times (2 * 10ml), then with 2 times (2 * 10ml) of sodium hydrogen carbonate solution washing, with saturated common salt water washing 2 times (2 * 10ml), organic layer is rear with anhydrous magnesium sulfate drying with saturated common salt washing, decompression is used silica gel chromatography column purification (ethyl acetate/petroleum ether 1:1, R after removing volatile solvent
f=0.22), obtain intermediate 4, yellow solid 17.9mg, yield 70%.
NMR, MS analysis confirmation product:
1H?NMR?(400?MHz,?CDCl
3)?δ:?7.46?(d,?J?=?7.1?Hz,?1H),?7.27?(d,?J?=?2.7?Hz,?1H),?7.17-7.11?(m,?2H),?6.75?(s,?1H),?3.96?(s,?2H),?2.79?(q,?J?=?7.5?Hz,2H),?2.47?(s,?3H),?1.28?(dd,?J?=?14.7,?7.1?Hz,?3H);
13C?NMR?(100?MHz,?CDCl
3)?δ:?143.8?(C),?143.0?(C),?139.4?(C),?129.0?(C),?127.6?(CH),?125.7?(C),?125.5?(C),?124.7?(CH),?120.9?(CH),?113.8?(CH),?113.4?(C),?110.4?(CH),?54.6?(CH
2),?41.2?(CH
3),?23.1?(CH
2),?14.8?(CH
3);?EIMS?m/z:?256?[M+H]
+?.
(5) from intermediate 3s, prepare intermediate 5:4-ethenyl-5-methyl-8,9-bis (prop-2-ynyloxy)-5,6-dihydrophenanthridine:
Under nitrogen protection condition, intermediate 3(24.8mg, 0.1mmol) be dissolved in THF(5mL) in, then add sodium hydride (NaH)
?(180mg, 0.3mmol, 40%) and propine bromine (3-bromoprop-1-yne) (14mg, 0.3mmol, 80%), under room temperature, react 8 hours, after finishing, reaction adds ammonium chloride solution, then add extracted with diethyl ether 2 times (2 * 10ml), then with 2 times (2 * 10ml) of ammonium chloride solution washing, with saturated common salt water washing 2 times (2 * 10ml), organic layer is rear with anhydrous magnesium sulfate drying with saturated common salt washing, decompression is used silica gel chromatography column purification (ethyl acetate/petroleum ether 200:1, R after removing volatile solvent
f=0.21), obtain intermediate 5, yellow solid 25.6mg, yield 82%.
NMR, MS analysis confirmation product:
1H?NMR?(400?MHz,?CDCl
3)?δ?7.62?(s,?1H),?7.48?(d,?J?=?12.4?Hz,?2H),?7.24-7.14?(m,?2H),?6.92?(s,?1H),?5.75?(d,?J?=?19.0?Hz,?1H),?5.32?(d,?J?=?10.6?Hz,?1H),?4.88?–?4.77?(m,?4H),?4.06?(s,?2H),?2.56?(s,1H),?2.55?(s,?1H),?2.52?(s,?3H);?
13C?NMR?(151?MHz,?CDCl
3)?δ?159.12?(C),?156.17?(C),?146.12?(C),?139.32?(CH),?133.72?(CH),?129.17?(C),?127.56?(C),?124.57?(CH),?123.30?(CH),?120.88?(C),?118.76?(C),?114.12?(CH
2),?110.63?(CH),?106.21?(CH),?80.14?(C),?80.09?(C),?76.42?(CH),?76.36?(CH),?64.78?(CH
2),?64.71?(CH
2),?58.83?(CH
2),?42.68?(CH
3);?HREIMS?m/z?329.1420?[M]
+?(calcd?for?C
22H
19NO
2,?329.1416).
(6) from intermediate 4s, prepare intermediate 6:4-ethyl-5-methyl-8,9-bis (prop-2-ynyloxy)-5,6-dihydrophenanthridine
Under nitrogen protection condition, intermediate 4(25.5mg, 0.1mmol) be dissolved in THF(5mL) in, then add sodium hydride (NaH)
?(180mg, 0.3mmol, 40%) and propine bromine (3-bromoprop-1-yne) (14mg, 0.3mmol, 80%), under room temperature, react 8 hours, after finishing, reaction adds ammonium chloride solution, then add extracted with diethyl ether 2 times (2 * 10ml), then with 2 times (2 * 10ml) of ammonium chloride solution washing, with saturated common salt water washing 2 times (2 * 10ml), organic layer is rear with anhydrous magnesium sulfate drying with saturated common salt washing, decompression is used silica gel chromatography column purification (ethyl acetate/petroleum ether 200:1, R after removing volatile solvent
f=0.21), obtain intermediate 6, yellow solid 26.4mg, yield 80%.
NMR, MS analysis confirmation product:
1H?NMR?(400?MHz,?CDCl
3)?δ?
1H?NMR?(400?MHz,?CDCl
3)?δ?7.54?(d,?J?=?6.9?Hz,?1H),?7.46?(s,?1H),?7.23?–?7.12?(m,?2H),?6.91?(s,?1H),?4.83?(s,?2H),?4.80?(s,?2H),?4.02?(s,?2H),?3.09?–?2.99?(m,?2H),?2.86?–?2.74?(m,?2H),?2.47?(s,?3H),?1.29?–?1.17?(m,?3H);?;
13C?NMR?(100?MHz,?CDCl
3)?δ:?147.4?(C),?146.8?(C),?145.6?(C),?139.5?(C),?128.9?(C),?127.9?(CH),?126.8?(C),?126.3?(C),?124.6?(CH),?121.0?(CH),?113.1?(CH),?110.5?(CH),?78.6?(C),?78.4?(C),?75.9?(CH),?75.8?(CH),?57.2?(CH
2),?56.9?(CH
2),?54.8?(CH
2),?41.31?(CH
3),?23.1?(CH
2),?14.8?(CH
3);?ESIMS?m/z:?330[M-H]
-.
(7) prepare compound 7:2-Azidoethylamine
2-bromine ethylamine hydrobromide (2-Bromoethylamine hydrobromide) (500 mg, 2.44 mmol) and sodium azide (sodium azide) (475.9 mg, 7.32 mmol) are dissolved into H
2in O (2 mL), under 75 ° of C, then stirring reaction 21 h are cooled to 0 ° of C, add potassium hydroxide (KOH) (800 mg) and Et
2o (2 mL), extracted with diethyl ether 2 times (2 * 10ml) for water layer, organic layer is with using anhydrous magnesium sulfate drying after saturated common salt washing, and decompression is used silica gel chromatography column purification (chloroform/methanol 20:1, R after removing volatile solvent
f=0.21), obtain compound 5, yellow liquid 171 mg, 1.99 mmol, yield 82%.
NMR analysis confirmation product:
1H?NMR?(400?MHz,?CDCl
3)?δ:?1.27?(s,?2?H,?NH2),?2.80–2.84?(m,?2?H,?CH
2N
3),?3.30?(t,?J?=?5.7?Hz,?2?H,?CH
2NH
2);
13C?NMR?(100?MHz,?CDCl3)?δ:?41.2?(CH
2NH
2),?54.6?(CH
2N
3)。
(8) prepare compound hlyc60:4-ethyl-5-methyl-8,9-bis (prop-2-tri-azole-ethylamineoxy)-5,6-dihydrophenanthridine
Compound 6(33.1mg, 0.1mmol) with compound 7(30.1mg, 0.4mmol) be dissolved to tBuOH(5mL) in, sodium ascorbate (sodium ascorbate) (19.8mg, 0.1mmol) and copper sulfate (1.8mg, 0.01) add water (2mL), then the aqueous solution is added in t-BuOH solution, at 50 ℃, stirring reaction is 12 hours, and underpressure distillation is used silica gel chromatography column purification (chloroform/methanol 25:1, R after removing solvent
f=0.23), obtain compound hlyc60, yellow solid 57.3mg, yield 60%.m.p.?196-197?°C。
NMR, MS analysis confirmation product:
1H?NMR?(400?MHz,?CDCl
3)?δ:?7.78?(m,?1H),?7.51–7.41?(m,?3H),?7.15–7.08?(m,?3H),?5.23–5.16?(m,?8H),?4.52–4.43?(m,?2H),?4.42?(s,?1H),?3.50?(s,?2H),?3.45?(s,?2H),?2.78?(d,?J?=?8?Hz,?2H),?2.44?(s,?3H),?1.27?(t,?J?=?8.0?Hz,?3H);
13C?NMR?(100?MHz,?CDCl
3)?δ:?147.17?(C),?144.05?(C),?139.44?(C),?135.99?(C),?134.83?(CH),?134.03?(C),?128.80?(C),?128.44?(C),?124.75?(CH),?124.51?(CH),?121.62?(CH),?121.55?(CH),?115.64?(C),?115.55?(C),?110.23?(CH),?109.84?(CH),?64.27?(CH
2),?63.26?(CH
2),?54.96?(CH
2),?50.78?(CH
2),?50.61?(CH
2),?41.65?(CH
3),?40.29?(CH
2),?39.41?(CH
2),?29.91?(CH
2),?15.27?(CH
3);?HREIMS?m/z?503.2741?[M]+?(calcd?for?C
26H
33N
9O
2,?503.2757).
(9) prepare compound hlyc68:4-ethyl-5-methyl-8,9-bis (prop-2-tri-azole-ethanediamideoxy)-5,6-dihydrophenanthridine
Compound hlyc60(50mg, 0.1mmol at 0 ℃) be dissolved in pyridine (5mL), add under diacetyl oxide (100 μ L) normal temperature stirring reaction 12 hours, add saturated NaHCO
3solution is used silica gel chromatography column purification (chloroform/methanol 9:1, R after regulating reaction solution pH 8-9 underpressure distillation to remove organic solvent
f=0.34), obtain compound hlyc68, yellow solid 46.3mg, yield 62%.
NMR, MS analysis confirmation product:
1H?NMR?(500?MHz,?CDCl
3?)?δ?7.99?(s,?1H),?7.89?–?7.81?(m,?2H),?7.47?(s,?1H),?7.32-7.29?(m,?2H),?7.13?(dd,?J?=?16.0,?3.7?Hz,?1H),?5.56?–?5.42?(m,?3H),?5.41-5.12?(m,?5H),?4.58-4.43?(m,?2H),?3.80?–?3.64?(m,?4H),?2.79?(m,?2H),?2.68?(s,?3H),?1.92?(s,?3H),?1.90?(s,?3H),?1.25?(m,?3H);?
13C?NMR?(125?MHz,?CDCl
3)?δ?172.2,?171.9,?149.7,?149.4,?146.1,?142.9,?142.6,?130.7,?129.3,?126.1,?125.1,?124.8,?124.4,?122.7,?122.0,?121.9,?112.6,?110.9,?56.2,?56.0,?51.4,?50.4,?50.3,?39.8,?36.8,?36.3,?28.6,?27.1,?26.9,?14.1.HREIMS?m/z?587.2960?[M]+?(calcd?for?C
30H
37N
9O
4,?587.2969).
(10) prepare compound hlyc67:4-ethenyl-5-methyl-8,9-bis (prop-2-tri-azole-ethylamineoxy)-5,6-dihydrophenanthridine
Compound 5(33.1mg, 0.1mmol) with compound 7(30.1mg, 0.4mmol) be dissolved to tBuOH(5mL) in, sodium ascorbate (sodium ascorbate) (19.8mg, 0.1mmol) and copper sulfate (1.8mg, 0.01) add water (2mL), then the aqueous solution is added in t-BuOH solution, at 50 ℃, stirring reaction is 12 hours, and underpressure distillation is used silica gel chromatography column purification (chloroform/methanol 25:1, R after removing solvent
f=0.46), obtain compound hlyc67, yellow solid 56.1mg, yield 57%.
NMR, MS analysis confirmation product:
1H?NMR?(500?MHz,?CDCl
3?)?δ?7.92?(s,?1H),?7.88?–?7.84?(m,?1H),?7.61?(s,?1H),?7.44?–?7.27?(m,?2H),?7.19?–?7.12?(m,?2H),?6.97?–?6.88?(m,?1H),?5.81?–?5.73?(m,?1H),?5.68?–?5.51?(m,?5H),?5.19?(s,?2H),?5.11?(s,?2H),?4.94?(s,?1H),?4.67?(s,?1H),?3.33?–?3.21?(m,?4H),?2.77?(s,?3H);?
13C?NMR?(125?MHz,?CDCl
3?)?δ?150.4,?148.1,?146.6,?144.1,?143.9,?137.7,?128.2,?126.1,?125.9,?125.3,?125.1,?124.1,?123.3,?123.0,?115.3,?115.1,?113.8,?111.1,?59.1,?58.8,?52.4,?52.2,?49.1,?40.3,?40.2,?39.9;?HREIMS?m/z?501.2613?[M]
+?(calcd?for?C
26H
31N
9O
2,?501.2601).
(11) prepare compound hlyc69:4-ethenyl5-methyl-8,9-bis (prop-2-tri-azole-ethanediamideoxy)-5,6-dihydrophenanthridine
Compound hlyc67(51mg, 0.1mmol at 0 ℃) be dissolved in pyridine (5mL), add under diacetyl oxide (100 μ L) normal temperature stirring reaction 12 hours, add saturated NaHCO
3solution is used silica gel chromatography column purification (chloroform/methanol 12:1, R after regulating reaction solution pH 8-9 underpressure distillation to remove organic solvent
f=0.44), obtain compound hlyc69, yellow solid 48.1mg, yield 61%.
NMR, MS analysis confirmation product:
1H?NMR?(500?MHz,?CDCl
3?)?δ?7.93?–?7.91?(m,?1H),?7.86?(s,?1H),?7.69?(s,?1H),?7.51?–?7.37?(m,?2H),?7.28?–?7.15?(m,?2H),?6.91?–?6.84?(m,?1H),?5.88?–?5.79?(m,?1H),?5.62?–?5.50?(m,?5H),?5.14?(s,?2H),?5.10?(s,?2H),?4.76?(s,?1H),?4.62?(s,?1H),?3.67?–?3.54?(m,?4H),?2.98?(s,?3H),?1.94?(s,?3H),?1.91?(s,?3H);
?13C?NMR?(125?MHz,?CDCl
3?)?δ?174.3,?174.2,?150.1,?148.9,?146.4,?143.8,?143.6,?138.7,?128.6,?126.8,?125.8,?125.2,?125.0,?122.8,?121.3,?121.1,?116.4,?115.1,?112.6,?111.0,?55.70,?55.6,?50.7,?51.4,?51.3,?39.8,?36.8,?36.6,?22.4,?22.1;?HREIMS?m/z?585.2821?[M]
+?(calcd?for?C
30H
35N
9O
4,?585.2812).
Embodiment 2:
Embodiment 1 gained compound activates the active result of Wnt signal path as table 1.
Table 1 compound activates the active result of Wnt signal path
Sample title |
The compound concentration that synergistic activation Wnt reporter gene is one times |
HLYC-60 |
1.25μM |
HLYC-67 |
2.5μM |
HLYC-68 |
1.25μM |
HLYC-69 |
5μM |
Experimental result:
Compound hlyc60, hlyc67, hlyc68 and hlyc69 can activate to depend on the form of Wnt3a acceptor the Reporter System of canonical Wnt signal pathway.
The present invention utilizes the Reporter System SCREENED COMPOUND of canonical Wnt signal pathway.Find compound hlyc60, hlyc67, hlyc68 and hlyc69 can work in coordination with the Reporter System (Fig. 1) of the activation canonical Wnt signal pathway of Wnt3a dose-dependently.
Embodiment 3:
The compound combination medicinal tablet of embodiment 1:
The compound of the embodiment of the present invention 1 is as the preparation of the drug regimen tablet of effective constituent: use the compound of embodiment 1 as active constituents of medicine, described in use table 2, vehicle is as the adjunct ingredient of preparing medicinal composition tablet, proportionally proportioning is made the tablet samples of every compound medicine composition 5 ~ 60mg that contains embodiment 1, and table 2 provides the formula rate of conventional tablet:
Bulk drug and the accessory formula of the compound combination medicinal tablet of table 2 embodiment of the present invention 1
The method that the compound of the embodiment of some amount 1 and vehicle auxiliary material is prepared into various dose tablet formulation is that several vehicle auxiliary materials are evenly mixed with bulk drug, add 1% sodium cellulose glycolate solution to make in right amount soft material, the granulation of sieving, wet grain is dried and is sieved whole, adds Magnesium Stearate and talcum powder mix rear compressing tablet and get final product.
Embodiment 4:
Compound combination pharmaceutical dosage form-capsule of embodiment 1:
The compound that contains embodiment 1 is as the preparation of the drug regimen capsule preparations of effective constituent: use the compound sample of embodiment 1 as active constituents of medicine, in use table 3, several vehicle are as the adjunct ingredient of preparing medicinal composition tablet, proportionally proportioning is made the capsule preparations of the compound medicine composition 5 ~ 50mg that contains embodiment 1 in every capsules, and table 3 provides the formula rate of conventional capsule preparation:
Bulk drug and the accessory formula of the compound combination pharmaceutical capsule preparation of table 3 embodiment 1
The method that the compound sample of the embodiment of some amount 1 and vehicle auxiliary material is prepared into capsule preparations is: the compound of several vehicle auxiliary materials and embodiment 1 is even, add 1% sodium cellulose glycolate solution appropriate, make wet grain and dry the whole grain that sieves, add Magnesium Stearate to mix, insert capsule and make; Or do not use granulation step, and directly the compound of embodiment 1 is mixed with several vehicle auxiliary materials, after sieving, directly incapsulate and make.
Embodiment 5:
By the method for embodiment 1, first make the compounds of this invention, injection liquid assistant agent used, injects respectively water routinely, essence filter, and injection liquid is made in embedding sterilizing.
Embodiment 6:
By the method for embodiment 1, first make the compounds of this invention, it is dissolved in respectively in sterile water for injection, stirring makes molten, with aseptic suction funnel, filter, more aseptic essence filter, being sub-packed in 2 ampoules, after frozen drying, aseptic sealing by fusing obtains powder injection.
The medicine of the compound that use contains embodiment 1 is the various medicines that use the compound contain embodiment 1 to manufacture as active constituents of medicine.
The dosage scope of the compound sample of embodiment 1, is used the compound composition of embodiment 1 as active constituents of medicine, and every day, dosage feature was within the scope of 5 ~ 200mg.
Above embodiment is for embodiment disclosed by the invention being described, can not being interpreted as limitation of the present invention.In addition, in various modifications listed herein and invention, the variation of method, composition, is apparent to those skilled in the art without departing from the scope and spirit in the present invention.Although the present invention has been carried out to concrete description in conjunction with multiple concrete preferred embodiment of the present invention, should be appreciated that the present invention should not only limit to these specific embodiments.In fact, various as above concerning those skilled in the art apparent modification obtain invention and all should comprise within the scope of the invention.